Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 30, 2009
Biased hormonal therapy duration analysis makes results uninterpretable
Catherine M Tangen, Bryan H Goldman, Gregory P Swanson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 15, 2013
Modeling the relationship between progression-free survival and overall survival: the phase II/III trial
Mary W Redman, Bryan H Goldman, Michael LeBlanc, et al.
Cancer
|
June 29, 2006
The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of Southwest Oncology Group Study 8894
Tomasz M Beer, Catherine M Tangen, Lisa B Bland, et al.
Leukemia & Lymphoma
|
August 10, 2011
A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517
Mark H Kirschbaum, Bryan H Goldman, Jasmine M Zain, et al.
Haematologica
|
January 25, 2012
Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone
Daniel O Persky, David Dornan, Bryan H Goldman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 7, 2012
Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414)
Michael B Tomblyn, Bryan H Goldman, Charles R Thomas, et al.
Cancer
|
June 12, 2009
Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy
Guru Sonpavde, Bryan H Goldman, V O Speights, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 2007
Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group
Christopher W Ryan, Bryan H Goldman, Primo N Lara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 26, 2011
S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma
Lawrence P Leichman, Bryan H Goldman, Pierre O Bohanes, et al.
American Journal of Hematology
|
March 18, 2014
Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma
Heather L Gustafson, Song Yao, Bryan H Goldman, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 30, 2009
Biased hormonal therapy duration analysis makes results uninterpretable
Catherine M Tangen, Bryan H Goldman, Gregory P Swanson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 15, 2013
Modeling the relationship between progression-free survival and overall survival: the phase II/III trial
Mary W Redman, Bryan H Goldman, Michael LeBlanc, et al.
Cancer
|
June 29, 2006
The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of Southwest Oncology Group Study 8894
Tomasz M Beer, Catherine M Tangen, Lisa B Bland, et al.
Leukemia & Lymphoma
|
August 10, 2011
A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517
Mark H Kirschbaum, Bryan H Goldman, Jasmine M Zain, et al.
Haematologica
|
January 25, 2012
Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone
Daniel O Persky, David Dornan, Bryan H Goldman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 7, 2012
Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414)
Michael B Tomblyn, Bryan H Goldman, Charles R Thomas, et al.
Cancer
|
June 12, 2009
Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy
Guru Sonpavde, Bryan H Goldman, V O Speights, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 2007
Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group
Christopher W Ryan, Bryan H Goldman, Primo N Lara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 26, 2011
S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma
Lawrence P Leichman, Bryan H Goldman, Pierre O Bohanes, et al.
American Journal of Hematology
|
March 18, 2014
Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma
Heather L Gustafson, Song Yao, Bryan H Goldman, et al.
Page
of 1